Symptom status and the desire for Helicobacter pylori confirmatory testing after eradication therapy in patients with peptic ulcer disease

American Journal of Medicine

Volumn 107, Issue 2, 1999, Pages 133-136

  Fendrick, A Mark ^a,b   Chey, William D ^b   Magaret, Nathan ^c   Palaniappan, Jyoti ^b   Fennerty, M Brian ^c  

^a Innov Cost Effectiveness S ^*  (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c Division of Gastroenterology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; PROTON PUMP INHIBITOR;

ARTICLE; CLINICAL ARTICLE; COST; ERADICATION THERAPY; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HELICOBACTER PYLORI; HUMAN; MALE; PEPTIC ULCER; PRIORITY JOURNAL; RECURRENT DISEASE; TREATMENT OUTCOME;

BREATH TESTS; EDUCATIONAL STATUS; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INCOME; MALE; MIDDLE AGED; PEPTIC ULCER; UNITED STATES; UREA;

EID: 0032816873     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(99)00196-5     Document Type: Article

References (12)

1. Helicobacter pylori in peptic ulcer disease. JAMA. 272:1994;65-69.
2. Sonnenberg A., Schwartz J.S., Cutler A.F., Vakil N., Bloom B.S. Cost savings in duodenal ulcer therapy through Helicobacter pylori eradication compared with conventional therapies results of a randomized, double-blind, multicenter trial. Gastrointestinal Utilization Trial Study Group . Arch Intern Med. 158:1998;852-860.
3. Fennerty M.B., Lieberman D.L., Magaret N. Effectiveness of Helicobacter pylori treatment regimens in clinical practice a community based outcomes study . Gastroenterology. 112:1997;A14.
4. Report of the Digestive Health Initiative: international update on Helicobacter pylori. Gastroenterology. 1997;113:S4-S8.
5. McColl K.E.L., El-Nujumi L.S., El-Omar E.M., et al. Assessment of symptomatic response as a predictor of Helicobacter pylori status following eradication therapy in patients with ulcer. Gut. 42:1998;618-622.
6. Penston J.G., Mistry K.R. Eradication of Helicobacter pylori in general practice. Aliment Pharmacol Ther. 10:1996;139-145.
7. Graham D.Y. Can therapy ever be denied for Helicobacter pylori infection? Gastroenterology. 113:1997;S113-S117.
8. Abu-Mahfouz M.Z., Prasad V.M., Santogade P., Cutler A.F. Helicobacter pylori recurrence after successful eradication 5-year follow-up in the United States . Am J Gastroenterol. 92:1997;2025-2028.
9. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Helicobacter pylori. Schistosomes, liver flukes and Helicobacter pylori: views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon: IARC, 1994:177-240.
10. 14C-urea breath test by a pH dependent mechanism. Am J Gastroenterol. 92:1997;446-450.
11. Laine L., Estrada R., Trujillo M., Knigge K., Fennerty B. Effect of proton-pump inhibitor therapy on diagnostic testing for Helicobacter pylori. Ann Intern Med. 129:1998;547-550.
12. Donaldson C., Shackley P., Abdalla M. Using willingness to pay to value close substitutes carrier screening for cystic fibrosis revisited . Health Econ. 6:1997;145-159.